Skip to main content
Erschienen in: BMC Gastroenterology 1/2024

Open Access 01.12.2024 | Research

Relationship between observation time and detection rate of focal lesions in Esophagogastroduodenoscopy: a single-center, retrospective study

verfasst von: Li Dong, Xiaodan Zhang, Yuting Xuan, Peiling Xiong, Yumei Ning, Bing Zhang, Fan Wang, Qiu Zhao, Jun Fang

Erschienen in: BMC Gastroenterology | Ausgabe 1/2024

Abstract

Background

Current studies have shown that longer observation time can improve neoplastic detection rate. This study aimed to clarify whether endoscopists with longer observation times can detect more focal lesions.

Methods

Based on the mean examination time for Esophagogastroduodenoscopy (EGD) without biopsy, endoscopists were divided into fast and slow groups, and the detection rate of focal lesions was compared between the two groups. Univariate analysis, multivariate analysis and restricted cubic spline were used to explore the factors of focal lesion detection rate.

Results

Mean examination time of EGD without biopsy was 4.5 min. The cut-off times used were 5 min. 17 endoscopists were classified into the fast (4.7 ± 3.6 min), and 16 into the slow (7.11 ± 4.6 min) groups. Compared with fast endoscopists, slow endoscopists had a higher detection rate of focal lesions (47.2% vs. 51.4%, P < 0.001), especially in the detection of gastric lesions (29.7% vs. 35.9%, P < 0.001). In univariate and multivariate analyses, observation time, patient age and gender, expert, biopsy rate, and number of images were factors in FDR. There is a nonlinear relationship between observation time and FDR.

Conclusion

Longer examination time improves the detection rate of focal lesions. Observation time is an important quality indicator of the EGD examination.
Begleitmaterial
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12876-024-03157-3.
Li Dong and Xiaodan Zhang contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer death in the world [1]. Esophagogastroduodenoscopy (EGD) is a common screening and diagnostic modality for gastrointestinal malignancy [2]. EGD has a high negative predictive value, and its false-negative rate is estimated to be between 10% and 20% [37]. Missed cancers are detected during follow-up endoscopy. Missed diagnosis of cancer during endoscopy is associated with several factors modifies, including missed lesions, inadequate follow-up lesions, inadequate monitoring of precancerous lesions, and the development of new tumors [8]. The risk of missed cancer is associated with the quality of EGD. High-quality endoscopy can improve the detection rate of early-stage gastric cancer and reduce cancer-related mortality. Endoscopic quality indicators include premedication, photo documentation, reporting, observation time, biopsy rate/protocol, endoscopy education, image-enhanced endoscopy, artificial intelligence [9]. Multiple observation studies have demonstrated that observation time to be an important and independent indicator of endoscopic quality [3, 10, 11]. Prolonged inspection time (> 1 min per centimeter) in Barrett’s esophagus increases the detection rate of high-grade dysplasia or adenocarcinoma [12]. Using 7 min as a cut-off time, slow endoscopists were more likely to detect high-risk lesions and neoplastic lesions than fast endoscopists [3]. The examination time was defined from the time the endoscope reached into the duodenum to the time it was withdrawn, using 3 min as the cut-off time, a higher proportion of neoplasms were detected by slow endoscopists compared to fast endoscopists [11]. Current studies have shown that longer observation time can improve neoplastic detection rate, but there are no studies on the relationship between observation time and overall focal lesion detection rate (FDR), and the effect of observation time on the detection rate of lesions in different parts of the upper gastrointestinal tract. Therefore, we investigated the observation time and lesion detection rate of each endoscopist. This study aimed to clarify whether endoscopists with longer observation times can detect more focal lesions, and shows the effect of observation time on the detection rate of different parts of the upper gastrointestinal tract. Assess the relationship between observation time and focal lesion detection.

Methods

Study design

Participants

In this single-center retrospective observational study, we reviewed a database of consecutive examinees who underwent outpatient EGD at the Endoscopy Center of Zhongnan Hospital of Wuhan University from January 2020 to June 2023. The exclusion criteria were as follows: patients < 18 years old, patients with a history of gastrointestinal surgery, therapeutic endoscopy, surveillance endoscopy, patients receiving oral anticoagulants regularly, patients with serious organic diseases of the heart, lung, liver or kidney, gastric retention or excess fluid in the stomach, performed by trainee, incomplete data. Informed consent was obtained from each patient included in the study. The study protocol was approved by the Ethics Committee of Zhongnan Hospital of Wuhan University.

Endoscopists and EGD examination

The endoscopists participating in this study had independently completed over 1,000 EGD examinations. An endoscopist with more than 10 years of experience in endoscopy is defined as expert [13]. Consistent with previous research methods [3, 11], Endoscopists were divided into fast and slow groups based on the mean observation time for EGDs without a biopsy. Observation time is defined as the time from capturing the first image in the pharynx to removing the endoscope. It is automatically measured by the endoscopic system and recorded in a database. All EGDs were performed using GIF-H260 and GIF-H290 endoscopies (Olympus Optical Co. Ltd., Tokyo, Japan). When using endoscopes, conventional white-light imaging and narrow-band imaging are used alternately. Narrow-band imaging was used during withdrawal from the esophagus. If suspicious lesions are found, narrow-band imaging should be used for further observation, and a biopsy should be performed as indicated. During EGD, we usually capture 40–60 images and the digital images are automatically saved in the endoscopic system. Before endoscopy, pharyngeal anesthesia is performed with a solution of lidocaine. Intravenous anesthesia is given at the patient’s request. According to the guidelines regarding sedation for gastroenterological endoscopy, midazolam is given intravenously and pethidine hydrochloride is given in patients with insufficient sedation.

Definitions and outcomes

The primary outcome was the overall focal lesion detection rate. The FDR was calculated as the proportion of EGD in which at least one of the focal lesions were detected. The focal lesions including Barrett’s esophagus, benign tumor of the esophagus, esophageal cancer, reflux esophagitis, esophageal candidiasis, esophageal ectopic gastric mucosa, hiatal hernia, esophageal diverticulum, gastric ulcer, gastric polyps, advanced stages of atrophic gastritis [14], intestinal metaplasia, submucosal tumors of the gastric, gastric cancer, extra gastric compression, gastric diverticulum, duodenal ulcer, duodenal polyps, duodenal diverticulum and submucosal tumors of the duodenal. Secondary outcomes included detection rate of esophageal, gastric and duodenal focal lesions, endoscopic biopsy rate.

Statistical methods

The quantitative data are presented as mean ± standard deviation and compared using Student’s t-test if normally distributed, and otherwise described as median (interquartile range, IQR) and compared using the Mann-Whitney U test. We performed the Kolmogorov-Smirnov test for normality. Categorical variables were compared using the chi-squared test. We used the Spearman correlation coefficient to measure the relationship between examination time and lesion detection rate by endoscopists. Simple and multivariate logistic regression analysis was used to identify independent predictors for detecting focal lesions. The correlation between observation time and FDR was evaluated on a continuous scale using a restricted cubic spline based on a multivariate logistic regression model. All statistical analyses were performed using R software (version 4.2.2) and SPSS 26.0 (SPSS Inc., Chicago, III, USA). P values < 0.05 were considered statistically significant.

Results

Participants

A total of 39,114 participants underwent EGDs during the study period. Among them, we excluded EGDs from patients younger than 18 years (n = 144), patients with a history of gastrointestinal surgery (n = 1687), therapeutic endoscopy (n = 2181), surveillance endoscopy (n = 3027), patients receiving oral anticoagulants regularly (n = 284), patients with serious organic diseases of the heart, lung, liver or kidney (n = 186), gastric retention or excess fluid in the stomach (n = 379), performed by trainee (n = 12,846), incomplete data (n = 23) (Fig. 1). A total of 18,357 EGD examinations were included in the study. The median age of patients was 49.0 (35.0,58.0) years, and 8650 (47.1%) were male. A total of 13,946 (76.0%) EGD were performed under sedation.

Examination time and focal lesion detection rate

12,759 examinations (69.5%) did not collect biopsy specimens. Focal lesions were detected in 8,908 participants (51.5%). Mean examination time of EGD without biopsy was 4.5 min (range, 2–29 min). The cut-off times used were 5 min. 17 endoscopists were classified into the fast (mean duration, 4.7 ± 3.6 min), and 16 into the slow (mean duration, 7.11 ± 4.6 min) groups. There were considerable differences among endoscopists in mean examination time and detection rate of focal lesions (Table 1). Characteristics of the endoscopist, patient and EGDs in the fast and slow endoscopist groups are shown in Table 2.
Table 1
Number endoscopic procedures, examination time, and detection rates of focal lesion of each endoscopist
 
Endoscopist
Expert
Number of EGD
Number of EGD without biopsy (N, %)
Mean examination time of EGD (min) (Mean ± SD)
Number of EGDs detected with focal lesions (N, %)
Endoscopists with a short examination time (fast endoscopists)
2
NO
310
235 (75.8)
3.5 ± 3.1
129 (41.6)
4
YES
960
763 (79.5)
3.3 ± 2.9
394 (41.0)
5
NO
559
436 (78.0)
4.3 ± 3.9
215 (38.5)
8
YES
1098
803 (73.1)
4.6 ± 3.6
527 (48.0)
9
YES
2685
1857 (69.2)
5.6 ± 4.1
1266 (47.2)
11
NO
201
162 (80.6)
4.1 ± 2.5
53 (26.4)
16
YES
180
115 (63.9)
5.5 ± 2.9
128 (71.1)
17
NO
472
327 (69.3)
5.1 ± 3.0
190 (40.3)
18
YES
1008
750 (74.4)
4.4 ± 3.0
479 (47.5)
19
YES
371
233 (62.8)
5.4 ± 4.3
165 (44.5)
21
YES
220
110 (50.0)
5.7 ± 3.8
124 (56.4)
22
NO
275
130 (47.3)
5.9 ± 3.7
210 (76.4)
24
YES
596
502 (84.2)
3.8 ± 3.7
277 (46.5)
25
NO
578
293 (50.7)
5.4 ± 3.8
339 (58.7)
28
YES
1806
1317 (72.9)
3.9 ± 3.0
851 (47.1)
31
NO
574
428 (74.6)
4.9 ± 3.3
282 (49.1)
33
YES
708
559 (79.0)
5.6 ± 3.6
322 (45.5)
Endoscopists with a long examination time (slow endoscopists)
1
YES
405
284 (70.1)
7.9 ± 4.8
227 (56.0)
3
YES
533
311 (58.3)
7.3 ± 5.0
310 (58.2)
6
YES
96
64 (66.7)
6.0 ± 4.0
33 (34.4)
7
NO
433
273 (63.0)
6.7 ± 4.9
189 (43.6)
10
NO
609
443 (72.7)
7.7 ± 4.3
322 (52.9)
12
YES
322
254 (78.9)
5.8 ± 4.2
145 (45.0)
13
YES
137
51 (37.2)
9.0 ± 4.4
94 (68.6)
14
YES
333
225 (67.6)
8.8 ± 6.7
200 (60.1)
15
NO
241
127 (52.7)
6.9 ± 3.7
128 (53.1)
20
NO
259
149 (57.5)
7.9 ± 4.2
167 (64.5)
23
NO
420
250 (59.5)
7.7 ± 3.4
226 (53.8)
26
YES
638
469 (73.5)
6.1 ± 4.4
254 (39.8)
27
NO
395
308 (78.0)
5.7 ± 2.9
173 (43.8)
29
YES
212
110 (51.9)
7.6 ± 4.7
112 (52.8)
30
NO
572
309 (54.0)
6.3 ± 4.2
315 (55.1)
32
NO
151
112 (74.2)
8.9 ± 4.7
62 (41.1)
Total
33
18
18,357
12,759 (69.5)
5.5 ± 4.1
8908 (48.5)
EGD, Esophagogastroduodenoscopy
Table 2
Characteristics of the endoscopist, patient and EGDs in the fast and slow endoscopist groups
 
Examinations by endoscopists with a short examination time (fast endoscopists)
(N = 12,601)
Examinations by endoscopists with a long examination time (slow endoscopists)
(N = 5756)
P value
Endoscopist
   
 Male, n (%)
6509 (51.7)
1885 (32.7)
< 0.001
 Expert, n (%)
9632 (76.4)
2676 (46.5)
< 0.001
Patient
   
 Male (N, %)
5838 (46.3)
2812 (48.9)
< 0.001
 Age, M (IQR)
50.0 (36.0,59.0)
48.0 (34.0,58.0)
< 0.001
Number of images, M (IQR)
58 (44,76)
59 (45,77)
< 0.05
Sedation (N, %)
10,000 (79.4%)
3946 (68.6%)
< 0.001
Biopsy specimen taken (N, %)
3581 (28.4%)
2017 (35.0%)
< 0.001

Detection rate of focal lesions

Compared with fast endoscopists, the overall focal lesion detection rate was higher among slow endoscopists (47.2% vs. 51.4%, P < 0.001). The most important difference between fast and slow endoscopists is the detection rate of gastric lesions. The detection rate of gastric lesions in slow endoscopists was significantly higher than fast endoscopists (29.7% vs. 35.9%, P < 0.001). Slow endoscopists have a higher detection rate of atrophic gastritis, gastric polyps, and gastric submucosal tumors than fast endoscopists. Fast endoscopists have a high detection rate of intestinal metaplasia. In esophageal and duodenal lesions, there was no statistically significant difference in the detection rate of focal lesions between fast and slow endoscopists (esophageal lesions: 17.0% vs. 15.9%, P > 0.05; duodenal lesions: 10.5% vs. 11.1%, P > 0.05) (Table 3).
Table 3
Lesions detected in the fast and slow endoscopist groups
 
Examinations by endoscopists with a short examination time (fast endoscopists)
(N = 12,601)
Examinations by endoscopists with a long examination time (slow endoscopists)
(N = 5756)
P value
Focal lesion, n (%)
5951 (47.2)
2957 (51.4)
< 0.001
Esophageal lesions, n (%)
2145 (17.0)
913 (15.9)
> 0.05
 Barrett’s esophagus, n (%)
380 (3.0)
114 (2.0)
< 0.001
 Benign tumors of the esophagus, n (%)
174 (1.4)
94 (1.6)
> 0.05
 Esophageal cancer, n (%)
45 (0.4)
22 (0.4)
> 0.05
 Reflux esophagitis, n (%)
1189 (9.4)
485 (8.4)
< 0.05
 Esophageal candidiasis, n (%)
33 (0.3)
24 (0.4)
> 0.05
 Esophageal ectopic gastric mucosa, n (%)
344 (2.7)
149 (2.6)
> 0.05
 Hiatal hernia, n (%)
270 (2.1)
116 (2.0)
> 0.05
 Esophageal diverticulum, n (%)
6 (0.0)
12 (0.2)
< 0.05
Gastric lesions
3746 (29.7)
2065 (35.9)
< 0.001
 Gastric ulcer, n (%)
550 (4.4)
266 (4.6)
> 0.05
 Atrophic gastritis, n (%)
1536 (12.2)
951 (16.5)
< 0.001
 Atrophic gastritis with intestinal metaplasia, n (%)
293 (2.3)
80 (1.4)
< 0.001
 Gastric polyps, n (%)
1754 (13.9)
954 (16.6)
< 0.001
 Submucosal tumors of the gastric, n (%)
219 (1.7)
137 (2.4)
< 0.01
 Gastric cancer, n (%)
90 (0.7)
44 (0.8)
> 0.05
 Extra gastric compression, n (%)
24 (0.2)
19 (0.3)
> 0.05
 Gastric diverticulum, n (%)
6 (0.0)
4 (0.1)
> 0.05
Duodenal lesions, n (%)
1322 (10.5)
637 (11.1)
> 0.05
 Duodenal polyps, n (%)
90 (0.7)
62 (1.1)
< 0.05
 Duodenal ulcer, n (%)
1076 (8.5)
514 (8.9)
> 0.05
 Duodenal diverticulum, n (%)
51 (0.4)
20 (0.3)
> 0.05
 Submucosal tumors of the duodenal, n (%)
164 (1.3)
77 (1.3)
> 0.05
In all EGD, Observation time is linearly related to focal lesion detection rate and biopsy rate (r = 0.252, P < 0.001; r = 0.428, P < 0.001). The focal lesion detection rate was strongly correlated with the biopsy rate (r = 0.354, P < 0.001). According to the average observation time and focal lesion detection rate of each endoscopist, it was found that the observation time was linearly related to the lesion detection rate (r = 0.449, P < 0.01) (Fig. 2).

Factors associated with detection of focal lesions

In univariate analysis, observation time, patient age, male patient, non-expert, slow group endoscopist, biopsy rate, and number of images were significantly associated with focal lesion detection. Among them, the longer observation time and older patients are conducive to improving the detection rate of lesions. There was no statistically significant relationship between endoscopist sex, sedation and lesion detection rate. In multivariate analysis, observation time of more than 5 min, age > 40 years, male, non-expert, high biopsy rate, and more photographic recording were important factors in the detection of focal lesions (Table 4).
Table 4
Factors associated with detection of focal lesions
Variables
Focal lesions, n (%)
Univariate Analysis
OR (95 % CI, P value)
Multivariable analysis
OR (95 % CI, P value)
Times
Total
 
1.13 (1.12–1.14, P < 0.001)
1.04 (1.03–1.05, P < 0.001)
 
< 5
3549 (39.8%)
  
 
[5,10)
3998 (44.9%)
2.26 (2.12–2.41, P < 0.001)
1.42 (1.31–1.53, P < 0.001)
 
[10,15)
917 (10.3%)
3.00 (2.67–3.37, P < 0.001)
1.49 (1.30–1.70, P < 0.001)
 
[15,20)
285 (3.2%)
4.23 (3.38–5.28, P < 0.001)
1.95 (1.52–2.50, P < 0.001)
 
>=20
159 (1.8%)
3.27 (2.49–4.29, P < 0.001)
1.49 (1.10–2.02, P = 0.010)
Patient age
Total
 
1.04 (1.04–1.05, P < 0.001)
1.04 (1.03–1.04, P < 0.001)
 
[18,40)
1920 (21.6%)
  
 
[40,60)
4244 (47.6%)
2.22 (2.07–2.38, P < 0.001)
1.84 (1.70–1.98, P < 0.001)
 
[60,80)
2667 (29.9%)
4.47 (4.10–4.87, P < 0.001)
3.60 (3.28–3.95, P < 0.001)
 
>=80
77 (0.9%)
9.11 (5.44–15.27, P < 0.001)
8.31 (4.86–14.18, P < 0.001)
Patient gender
Female
4270 (47.9%)
  
 
Male
4638 (52.1%)
1.47 (1.39–1.56, P < 0.001)
1.45 (1.36–1.55, P < 0.001)
Endoscopist gender
Female
4857 (54.5%)
  
 
Male
4051 (45.5%)
0.98 (0.93–1.04, P = 0.508)
 
Expert
NO
3000 (33.7%)
  
 
YES
5908 (66.3%)
0.94 (0.88-1.00, P = 0.042)
0.92 (0.86–0.99, P = 0.028)
Group
FAST
5951 (66.8%)
  
 
SLOW
2957 (33.2%)
1.18 (1.11–1.26, P < 0.001)
0.98 (0.91–1.06, P = 0.590)
Biopsy
NO
4697 (52.7%)
  
 
YES
4211 (47.3%)
5.21 (4.86–5.59, P < 0.001)
3.66 (3.39–3.95, P < 0.001)
Sedation
NO
2122 (23.8%)
  
 
YES
6786 (76.2%)
1.02 (0.96–1.09, P = 0.522)
 
Number of images
Total
 
1.01 (1.01–1.01, P < 0.001)
1.01 (1.00-1.01, P < 0.001)
OR, odds ratio; CI, confidence interval
In restricted cubic spline regression, there was a significant nonlinear relationship between observation time and lesion detection rate (p for nonlinear < 0.001, Fig. 3). With the increase of observation time, the detection rate of lesions gradually increased until the curve stabilized after more than 10 min of observation time.

Discussion

In this retrospective study of 18,357 endoscopic examination data, we found that the longer the observation time during endoscopy, the higher the detection rate of focal lesions. Compared with fast endoscopists (< 5 min), slow endoscopists (> 5 min) had a higher detection rate of focal lesions, especially in the detection of gastric lesions. In univariate and multivariate analyses, we found that observation time, patient age and gender, non-expert, biopsy rate, and number of images were important factors in lesion detection. There is a nonlinear relationship between observation time and lesion detection, and with the increase of observation time, the lesion detection rate continues to increase until the lesion detection rate tends to stabilize after more than 10 min. The results of this study are consistent with those of previously published articles [3, 1012].
EGD is an important way to screen, diagnose and monitor gastrointestinal tumors. High-quality EGD can improve cancer detection rate and reduce cancer mortality. There is currently a lack of widely accepted and recognized endoscopic quality assessment protocols. Based on the currently published study, observation time is an important indicator of endoscopic quality [15, 16]. However, Current published studies have different definitions of observation time. In a retrospective analysis study of data from 111,962 participants, using a 3-minute cut-off time, more gastric adenomas or cancers were detected by slow endoscopists than by fast endoscopists (0.28% vs. 0.20%; P = 0.0054) [11]. The observation time for the study was defined as the time from the withdrawal of the endoscope from the second duodenal portion to the end of the EGD examination. This definition is similar to the definition of observation time in a colonoscopy. However, during endoscopic insertion, the endoscopist will observe the esophagogastric junction, antrum, pylorus, and duodenal bulb [17, 18]. Therefore, it is more accurate to use the time from insertion to endoscopic exit as the study metric compared with using endoscopic withdrawal time. Our study found that the slow endoscopists had a higher rate of lesion detection than the fast endoscopists, especially in the detection of gastric lesions. In the future, the fast endoscopists can extend the observation time of the stomach to obtain a higher lesion detection rate. In restricted cubic spline regression, it is found that there is a nonlinear relationship between observation time and lesion detection rate. Within less than 10 min, the detection rate of lesions increased with the increase of observation time, but after more than 10 min, the detection rate of lesions tended to stabilize. This suggests that longer observation time does not mean greater benefit. More research is needed to determine the cut-off time and whether there is an upper limit effect beyond which there is no benefit in lesion detection rates [19]. Slow endoscopists had a higher detection rate of atrophic gastritis while fast ones had a high rate of intestinal metaplasia. Endoscopic diagnosis of atrophic gastritis requires assessment of mucosal color and texture, appearance of submucosal blood vessels, and the architecture of the gastric rugae, followed by targeted examinations of focal abnormalities [20]. Therefore, slow endoscopists spend more time and have a higher detection rate. We found that fast group of experts has a great influence on the difference in the detection rate of atrophic gastritis with intestinal metaplasia. Expert can achieve high quality esophagogastroduodenoscopy with a high detection rate in short observation time (Suppl Table 1). However, it is difficult for non-experts to detect intestinal metaplasia quickly and accurately. Intestinal metaplasia requires pathological diagnosis and relies on biopsy material. Expert have extensive experience with biopsies and have a higher positive rate. Therefore, it is advisable to obtain a higher detection rate by increasing the observation time, especially for non-experts. In univariate and multivariate analyses, observation time, patient age, male, non-expert, biopsy rate, and number of images were related to lesion detection, while there was no statistically significant relationship between endoscopist’s sex, sedative use and lesion detection. We found that the top 4 endoscopists of number of EGD were all in the fast group, and all of them were expert. A large number of patients and high work pressure may result in decreasing in the detection rate of lesions. It differs from the conclusions of previous studies on Sedation. Sedation can significantly improve patient cooperation, satisfaction. The Asian consensus recommends the use of sedation to enhance the detection rate of superficial neoplasm of the esophagus and stomach [15]. A retrospective study suggested gastric polyps detection rate may be improved by inhibition of gastric muscle cramping with sedation [21]. Other studies have shown there was no statistically significant difference in the detection rate of precancerous lesions and early esophageal cancer between patients who underwent EGD screening with and without anesthesia assistance [22]. Sedation may improve the endoscopic detection rate of early cancer and high-grade intraepithelial neoplasia in the upper gastrointestinal tract probably through enhancing the use of accessary endoscopic techniques, prolonging observation time, and taking more biopsies in different locations [23].
There are several limitations in this study. First, this was a single-center, retrospective study. Second, a patient-selection bias might have been present. To reduce selection bias, we included all consecutive EGDs performed in a period where the staff of endoscopists was unchanged. Third, it is not possible to calculate the observation time of the esophagus, stomach, duodenum. The effect of biopsy time on observation time cannot be removed.
In conclusion, our study found that longer examination time improves the detection rate of focal lesions. Observation time is an important quality indicator of the EGD examination.

Declarations

The study protocol has been approved by the Medical Ethics Committee of Zhongnan Hospital of Wuhan University(2023239 K). Due to the retrospective nature of this study, the Medical Ethics Committee of Zhongnan Hospital of Wuhan University waived the need for written informed consent.
Not applicable.

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Anhänge

Electronic supplementary material

Below is the link to the electronic supplementary material.
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Zurück zum Zitat Gupta S, Li D, El Serag HB, Davitkov P, Altayar O, Sultan S, Falck-Ytter Y, Mustafa RA. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020;158(3):693–702.CrossRefPubMed Gupta S, Li D, El Serag HB, Davitkov P, Altayar O, Sultan S, Falck-Ytter Y, Mustafa RA. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020;158(3):693–702.CrossRefPubMed
3.
Zurück zum Zitat Teh JL, Tan JR, Lau LJ, Saxena N, Salim A, Tay A, Shabbir A, Chung S, Hartman M, So JB. Longer examination time improves detection of gastric cancer during diagnostic upper gastrointestinal endoscopy. Clin Gastroenterol Hepatol. 2015;13(3):480–487e482.CrossRefPubMed Teh JL, Tan JR, Lau LJ, Saxena N, Salim A, Tay A, Shabbir A, Chung S, Hartman M, So JB. Longer examination time improves detection of gastric cancer during diagnostic upper gastrointestinal endoscopy. Clin Gastroenterol Hepatol. 2015;13(3):480–487e482.CrossRefPubMed
4.
Zurück zum Zitat Wang YR, Loftus EV Jr., Judge TA, Peikin SR. Rate and predictors of interval esophageal and gastric cancers after Esophagogastroduodenoscopy in the United States. Digestion. 2016;94(3):176–80.CrossRefPubMed Wang YR, Loftus EV Jr., Judge TA, Peikin SR. Rate and predictors of interval esophageal and gastric cancers after Esophagogastroduodenoscopy in the United States. Digestion. 2016;94(3):176–80.CrossRefPubMed
5.
Zurück zum Zitat Chadwick G, Groene O, Riley S, Hardwick R, Crosby T, Hoare J, Hanna GB, Greenaway K, Cromwell DA. Gastric cancers missed during Endoscopy in England. Clin Gastroenterol H. 2015;13(7):1264–.CrossRef Chadwick G, Groene O, Riley S, Hardwick R, Crosby T, Hoare J, Hanna GB, Greenaway K, Cromwell DA. Gastric cancers missed during Endoscopy in England. Clin Gastroenterol H. 2015;13(7):1264–.CrossRef
6.
Zurück zum Zitat Hosokawa O, Tsuda S, Kidani E, Watanabe K, Tanigawa Y, Shirasaki S, Hayashi H, Hinoshita T. Diagnosis of gastric cancer up to three years after negative upper gastrointestinal endoscopy. Endoscopy. 1998;30(8):669–74.CrossRefPubMed Hosokawa O, Tsuda S, Kidani E, Watanabe K, Tanigawa Y, Shirasaki S, Hayashi H, Hinoshita T. Diagnosis of gastric cancer up to three years after negative upper gastrointestinal endoscopy. Endoscopy. 1998;30(8):669–74.CrossRefPubMed
7.
Zurück zum Zitat Yalamarthi S, Witherspoon P, McCole D, Auld CD. Missed diagnoses in patients with upper gastrointestinal cancers. Endoscopy. 2004;36(10):874–9.CrossRefPubMed Yalamarthi S, Witherspoon P, McCole D, Auld CD. Missed diagnoses in patients with upper gastrointestinal cancers. Endoscopy. 2004;36(10):874–9.CrossRefPubMed
8.
Zurück zum Zitat Pimenta-Melo AR, Monteiro-Soares M, Libanio D, Dinis-Ribeiro M. Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2016;28(9):1041–9.CrossRefPubMed Pimenta-Melo AR, Monteiro-Soares M, Libanio D, Dinis-Ribeiro M. Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2016;28(9):1041–9.CrossRefPubMed
10.
Zurück zum Zitat Kawamura T, Wada H, Sakiyama N, Ueda Y, Shirakawa A, Okada Y, Sanada K, Nakase K, Mandai K, Suzuki A, et al. Examination time as a quality indicator of screening upper gastrointestinal endoscopy for asymptomatic examinees. Dig Endosc. 2017;29(5):569–75.CrossRefPubMed Kawamura T, Wada H, Sakiyama N, Ueda Y, Shirakawa A, Okada Y, Sanada K, Nakase K, Mandai K, Suzuki A, et al. Examination time as a quality indicator of screening upper gastrointestinal endoscopy for asymptomatic examinees. Dig Endosc. 2017;29(5):569–75.CrossRefPubMed
11.
Zurück zum Zitat Park JM, Huo SM, Lee HH, Lee BI, Song HJ, Choi MG. Longer Observation Time increases proportion of Neoplasms detected by Esophagogastroduodenoscopy. Gastroenterology. 2017;153(2):460–469e461.CrossRefPubMed Park JM, Huo SM, Lee HH, Lee BI, Song HJ, Choi MG. Longer Observation Time increases proportion of Neoplasms detected by Esophagogastroduodenoscopy. Gastroenterology. 2017;153(2):460–469e461.CrossRefPubMed
12.
Zurück zum Zitat Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 2012;76(3):531–8.CrossRefPubMed Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 2012;76(3):531–8.CrossRefPubMed
13.
Zurück zum Zitat Unno S, Igarashi K, Saito H, Hirasawa D, Okuzono T, Tanaka Y, Nakahori M, Matsuda T. Assigning a different endoscopist for each annual follow-up may contribute to improved gastric cancer detection rates. Endosc Int Open. 2022;10(10):E1333–42.CrossRefPubMedPubMedCentral Unno S, Igarashi K, Saito H, Hirasawa D, Okuzono T, Tanaka Y, Nakahori M, Matsuda T. Assigning a different endoscopist for each annual follow-up may contribute to improved gastric cancer detection rates. Endosc Int Open. 2022;10(10):E1333–42.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, Garrido M, Kikuste I, Megraud F, Matysiak-Budnik T, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa De Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365–88.CrossRefPubMed Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, Garrido M, Kikuste I, Megraud F, Matysiak-Budnik T, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa De Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365–88.CrossRefPubMed
15.
Zurück zum Zitat Chiu PWY, Uedo N, Singh R, Gotoda T, Ng EKW, Yao K, Ang TL, Ho SH, Kikuchi D, Yao F, et al. An Asian consensus on standards of diagnostic upper endoscopy for neoplasia. Gut. 2019;68(2):186–97.CrossRefPubMed Chiu PWY, Uedo N, Singh R, Gotoda T, Ng EKW, Yao K, Ang TL, Ho SH, Kikuchi D, Yao F, et al. An Asian consensus on standards of diagnostic upper endoscopy for neoplasia. Gut. 2019;68(2):186–97.CrossRefPubMed
16.
Zurück zum Zitat Bisschops R, Areia M, Coron E, Dobru D, Kaskas B, Kuvaev R, Pech O, Ragunath K, Weusten B, Familiari P, et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2016;48(9):843–64.CrossRefPubMed Bisschops R, Areia M, Coron E, Dobru D, Kaskas B, Kuvaev R, Pech O, Ragunath K, Weusten B, Familiari P, et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2016;48(9):843–64.CrossRefPubMed
17.
Zurück zum Zitat Lee SH, Park YK, Cho SM, Kang JK, Lee DJ. Technical skills and training of upper gastrointestinal endoscopy for new beginners. World J Gastroenterol. 2015;21(3):759–85.CrossRefPubMedPubMedCentral Lee SH, Park YK, Cho SM, Kang JK, Lee DJ. Technical skills and training of upper gastrointestinal endoscopy for new beginners. World J Gastroenterol. 2015;21(3):759–85.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Secknus R. [Endoscopy of the upper gastrointestinal tract]. Internist (Berl). 2004;45(12):1407–16. quiz 1417– 1408.CrossRefPubMed Secknus R. [Endoscopy of the upper gastrointestinal tract]. Internist (Berl). 2004;45(12):1407–16. quiz 1417– 1408.CrossRefPubMed
19.
Zurück zum Zitat Namasivayam V, Uedo N. Quality indicators in the endoscopic detection of gastric cancer. DEN Open 2023, 3(1). Namasivayam V, Uedo N. Quality indicators in the endoscopic detection of gastric cancer. DEN Open 2023, 3(1).
20.
Zurück zum Zitat Shah SC, Piazuelo MB, Kuipers EJ, Li D. AGA clinical practice update on the diagnosis and management of Atrophic gastritis: Expert Review. Gastroenterology. 2021;161(4):1325–1332e1327.CrossRefPubMed Shah SC, Piazuelo MB, Kuipers EJ, Li D. AGA clinical practice update on the diagnosis and management of Atrophic gastritis: Expert Review. Gastroenterology. 2021;161(4):1325–1332e1327.CrossRefPubMed
21.
Zurück zum Zitat Chen MJ, Wu W, Pan S, Lin CJ, Dong LM, Chen ZF, Wu JS, Huang ZM. Sedated gastroscopy improves detection of gastric polyps. Exp Ther Med. 2018;16(4):3116–20.PubMedPubMedCentral Chen MJ, Wu W, Pan S, Lin CJ, Dong LM, Chen ZF, Wu JS, Huang ZM. Sedated gastroscopy improves detection of gastric polyps. Exp Ther Med. 2018;16(4):3116–20.PubMedPubMedCentral
22.
Zurück zum Zitat Liang M, Xu C, Zhang X, Zhang Z, Cao J. Effect of anesthesia assistance on the detection rate of precancerous lesions and early esophageal squamous cell cancer in esophagogastroduodenoscopy screening: a retrospective study based on propensity score matching. Front Med (Lausanne). 2023;10:1039979.CrossRefPubMed Liang M, Xu C, Zhang X, Zhang Z, Cao J. Effect of anesthesia assistance on the detection rate of precancerous lesions and early esophageal squamous cell cancer in esophagogastroduodenoscopy screening: a retrospective study based on propensity score matching. Front Med (Lausanne). 2023;10:1039979.CrossRefPubMed
23.
Zurück zum Zitat Zhou J, Li Z, Ji R, Wang P, Zhang A, Wu K, Liu C, Niu Q, Chu Y, Su X, et al. Influence of Sedation on the detection rate of Early Cancer and Precancerous lesions during Diagnostic Upper gastrointestinal endoscopies: a Multicenter Retrospective Study. Am J Gastroenterol. 2021;116(6):1230–7.CrossRefPubMed Zhou J, Li Z, Ji R, Wang P, Zhang A, Wu K, Liu C, Niu Q, Chu Y, Su X, et al. Influence of Sedation on the detection rate of Early Cancer and Precancerous lesions during Diagnostic Upper gastrointestinal endoscopies: a Multicenter Retrospective Study. Am J Gastroenterol. 2021;116(6):1230–7.CrossRefPubMed
Metadaten
Titel
Relationship between observation time and detection rate of focal lesions in Esophagogastroduodenoscopy: a single-center, retrospective study
verfasst von
Li Dong
Xiaodan Zhang
Yuting Xuan
Peiling Xiong
Yumei Ning
Bing Zhang
Fan Wang
Qiu Zhao
Jun Fang
Publikationsdatum
01.12.2024
Verlag
BioMed Central
Erschienen in
BMC Gastroenterology / Ausgabe 1/2024
Elektronische ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-024-03157-3

Weitere Artikel der Ausgabe 1/2024

BMC Gastroenterology 1/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.